Wordt geladen...
Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
BACKGROUND AND OBJECTIVES: Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody (mAb) that binds to the HER2 protein. PF-05280014 is being developed as a potential biosimilar to trastuzumab products marketed in the United States (trastuzumab-US) and European Union (trastuzumab-EU). Nonclini...
Bewaard in:
Hoofdauteurs: | , , , , , , , , , |
---|---|
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
Springer International Publishing
2014
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4176567/ https://ncbi.nlm.nih.gov/pubmed/25001079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-014-0103-4 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|